-
2023-506759-51-00
7
2024-03-29
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2023-503376-24-00
5
2024-03-20
Metastatic non-small cell lung cancer (NSCLC)
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2023-504472-24-00
4
2024-03-19
Early Idiopathic Parkinson’s disease (PD)
-
2024-514544-90-00
9
2024-03-11
Relapsed or refractory B-cell lymphoma
-
2023-505141-48-00
5
2024-03-07
Fibrosis
-
2023-504835-42-00
4
2024-02-29
Heart Failure (Heart Failure with Reduced Ejection Fraction)
-
2023-507441-29-00
5
2024-02-29
Pneumonia
-
2023-505251-43-00
5
2024-02-28
Primary Biliary Cholangitis
-
2022-501453-36-00
5
2024-02-23
Breast cancer
-
2023-504863-17-00
5
2024-02-21
1. Lupus Erythematosus, Cutaneous, Subacute
2. Chronic Cutaneous Lupus
-
2024-517363-24-00
4
2024-02-16
Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian,
-
2022-500531-36-00
4
2024-02-02
Type 1 diabetes mellitus
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2023-503327-26-00
5
2024-01-31
Sjogren's syndrome
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2022-503061-29-00
7
2024-01-22
Neoplasms benign malignant and unspecified (incl cysts and polyps). Me
-
2023-506572-27-00
3
2024-01-12
Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)
-
2024-516677-79-00
4
2024-01-11
Premature patients with bronchopulmonary dysplasia
-
2022-503092-28-00
5
2024-01-08
Relapsed/Refractory Follicular Lymphoma
-
2023-505911-19-00
4
2024-01-05
Acute Myeloid Leukemia
-
2023-504807-94-00
7
2023-12-26
Breast Cancer; Advanced solid tumors including but not limited to gyne
-
2022-502046-28-00
5
2023-12-22
HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C